We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00928304
First Posted: June 25, 2009
Last Update Posted: March 5, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Piramal Imaging SA
Results First Submitted: December 9, 2013  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Diagnostic
Conditions: Down Syndrome
Amyloid Beta-protein
Intervention: Drug: Florbetaben (BAY94-9172)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The study was conducted at two sites in the US.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
A total of 130 subjects were screened. 21 subjects were considered as screen failures and were not enrolled into the study. 9 subjects did not meet the inclusion/exclusion criteria. 10 subjects withdrew their consent. 1 subject was lost to follow-up and 1 subjected exceeded the weight limit for the camera.

Reporting Groups
  Description
Down Syndrome Group 39 Down Syndrome subjects received Florbetaben (BAY94-9172) : 300 megabecquerels (MBq) single IV injection of 2 to 10 mL
Healthy Volunteer Group 70 healthy volunteer subjects received Florbetaben (BAY94-9172): 300 MBq single IV injection of 2 to 10 mL

Participant Flow:   Overall Study
    Down Syndrome Group   Healthy Volunteer Group
STARTED   39   70 
COMPLETED   39   70 
NOT COMPLETED   0   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All Down Syndrome subjects and healthy volunteers enrolled into the study were included in the Baseline Analysis Population

Reporting Groups
  Description
Subjects Enrolled in Study All Down Syndrome and healthy volunteer subjects

Baseline Measures
   Subjects Enrolled in Study 
Overall Participants Analyzed 
[Units: Participants]
 109 
Age 
[Units: Participants]
 
<=18 years   0 
Between 18 and 65 years   109 
>=65 years   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 
Down Syndrome Group   46.3  (4.7) 
Healthy Volunteer Group   27.7  (5.1) 
Gender 
[Units: Participants]
 
Female   60 
Male   49 
Region of Enrollment 
[Units: Participants]
 
United States   109 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Sensitivity of the Independent Visual Assessment of Detecting Cerebral Amyloid-beta in Individuals With Down Syndrome and Specificity in Subjects Without Down Syndrome   [ Time Frame: 100-120 min ]

2.  Secondary:   Sensitivity Results in the Down Syndrome Age Subgroups   [ Time Frame: 100 - 120 min ]

3.  Secondary:   Quantitative Parameters Standard Uptake Value Ratio   [ Time Frame: 100 - 120 min p.i. ]

4.  Secondary:   Consistency Between Visual and Quantitative Efficacy   [ Time Frame: 100 - 120 min ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Juergen Hirschfeld
Organization: Piramal Imaging
phone: 49 30 461 1246 15
e-mail: juergen.hirschfeld@piramal.com



Responsible Party: Piramal Imaging SA
ClinicalTrials.gov Identifier: NCT00928304     History of Changes
Other Study ID Numbers: 14311
First Submitted: June 24, 2009
First Posted: June 25, 2009
Results First Submitted: December 9, 2013
Results First Posted: January 28, 2014
Last Update Posted: March 5, 2014